PLYX
Polaryx Therapeutics, Inc.Company Information
- Company Name
- Polaryx Therapeutics, Inc.
- CIK
- CIK0002075320
- Category
- <br>Emerging growth company
- Ticker: Exchange
- PLYX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PLYX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-27
- Last sale
- —
- Shares purchased (TTM)
- 91,320
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,111,087
- Shares outstanding
- 48,278,370
- Ownership
- 4.37%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -20.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Related Party | -0 | 0 | 0 | ||||||
Assets Current | |||||||||
| Cash And Cash Equivalents At Carrying Value | 12 | 3 | 5 | ||||||
| Prepaid Expense Current | 0 | 0 | - | ||||||
| Other Assets Current | - | 0 | 0 | ||||||
| Assets Current | 12 | 4 | 5 | ||||||
| Assets | 12 | 4 | 5 | ||||||
Liabilities Current | |||||||||
| Accounts Payable Current | 1 | 1 | 0 | ||||||
| Accrued Liabilities Current | 0 | 0 | - | ||||||
| Accrued Liabilities And Other Liabilities | 0 | 0 | 0 | ||||||
| Liabilities Current | 1 | 1 | 1 | ||||||
| Liabilities | 1 | 1 | 1 | ||||||
Stockholders Equity | |||||||||
| Common Stock Value | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 114 | 105 | 104 | ||||||
| Retained Earnings Accumulated Deficit | -104 | -102 | -100 | ||||||
| Stockholders Equity | 11 | 2 | 5 | ||||||
| Liabilities And Stockholders Equity | 12 | 4 | 5 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 40 | 40 | 40 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 560 | 560 | 560 | ||||||
| Common Stock Shares Issued | 50 | 47 | 47 | ||||||
| Shares Outstanding | 50 | 47 | 47 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPolaryx Therapeutics, Inc. (PLYX) — SEC Financial Statements & Analysis
Polaryx Therapeutics, Inc. (PLYX) is a pharmaceutical preparations company, incorporated in WY. Polaryx Therapeutics, Inc. trades on Nasdaq as: PLYX. Polaryx Therapeutics, Inc. (PLYX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Polaryx Therapeutics, Inc. carries a market cap of $128.42M, a P/B ratio of 11.74x, and an enterprise value of $116.88M. On the balance sheet, it maintains a current ratio of 13.53x, a quick ratio of 13.22x, working capital of $10.94M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.07, and net debt of $-11.54M. Figures sourced from SEC EDGAR.
- Market Cap
- $128.42M
- P/B TTM
- 11.74x
- Debt To Equity
- 0.08x
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Polaryx Therapeutics, Inc. in?
Polaryx Therapeutics, Inc. (PLYX) operates in the Pharmaceutical Preparations industry.
What exchange does PLYX trade on?
Polaryx Therapeutics, Inc. (PLYX) trades on the Nasdaq.
Where is Polaryx Therapeutics, Inc. incorporated?
Polaryx Therapeutics, Inc. is incorporated in WY.
When was Polaryx Therapeutics, Inc. (PLYX)'s most recent SEC filing?
Polaryx Therapeutics, Inc. (PLYX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is PLYX's market cap?
Polaryx Therapeutics, Inc. (PLYX) has a market capitalization of $128.42M as of 2026-06-30.